Equillium | 8-K: Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
Equillium | DEF 14A: Definitive information statements
Equillium | DEFA14A: Others
Equillium | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Equillium | 8-K: Current report
Equillium | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Equillium | 8-K: Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
Equillium | 8-K: Current report
Equillium | 8-K: Current report
Equillium | 8-K: Current report
Equillium | 8-K: Current report
Equillium | 8-K: Current report
Equillium | 8-K: Current report
Equillium | 8-K: Current report
Equillium | 8-K: Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
Equillium | 8-K: Current report
Equillium | 8-K: Current report
Equillium | 8-K: Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
Equillium | DEFA14A: Others
Equillium | DEF 14A: Definitive proxy statements
No Data